Chandan Bariya of Sankariya village of Limkheda Taluka was brought to the clinic of Samir Brahmbhat after complaining of severe abdominal pain. Tests demonstrated that the girl was suffering from a rare disorder called Rapunzel syndrome, where an individual pulls one’s hair out and then eats it. This condition normally...
Latest News
Columbus, Ohio – When Susan Powers went in for surgery to replace her hip in 2018, the last thing on her mind was cancer. But Powers’ pre-surgery blood work alarmed doctors enough that they recommended she see an oncologist immediately. Her daughter, Cheryl Spile, drove her to the hospital, where...
BEDMINSTER, N.J. — Matinas BioPharma (NYSE: MTNB), a clinical-stage biopharmaceutical company focused on delivering groundbreaking therapies using its lipid nanocrystal (LNC) platform delivery technology, announces alignment with the U.S. Food and Drug Administration (FDA) on the design of a single Phase 3 registration trial of MAT2203 in patients with invasive...
How can inflammatory responses be stimulated or inhibited? How do inflammasomes act as inflammatory switches at a molecular level? Prof. Dr. Matthias Geyer from the Institute of Structural Biology at University Hospital Bonn, the transdisciplinary research area “Life & Health” and the ImmunoSensation2 Cluster of Excellence at the University of...
First Patient Dosing Anticipated in Second Half of 2025 Additional Details to be Provided by Webinar in Coming Months MIDDLETON, Mass. — MavriX Bio, a clinical-stage biotechnology company focused on the development of transformative genetic therapies for Angelman syndrome (AS), today announced that the U.S. Food and Drug Administration (FDA) has...
MIDDLETON, Mass. — MavriX Bio, a clinical-stage biotechnology company focused on the development of transformative genetic therapies for Angelman syndrome (AS), today announced that the first patient has been dosed in the Phase 1/2 ASCEND-AS clinical trial of MVX-220, an investigational gene therapy for AS. The ASCEND-AS trial (NCT07181837) represents the...
MIDDLETON, Mass. — MavriX Bio, a clinical-stage biotechnology company focused on the development of transformative genetic therapies for Angelman syndrome (AS), today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for MVX-220, an investigational adeno-associated virus (AAV) gene therapy for the treatment of AS. “The...
Rochester, Minnesota – Mayo Clinic Comprehensive Cancer Center and Columbia University received a five-year, $10.6 million U54 center grant from the National Cancer Institute (NCI) to further study combining the molecular analysis of glioblastoma with MRI. Glioblastoma is a fast-growing and aggressive brain tumor that begins as a growth of cells in the brain or spinal cord. As...
ROCHESTER, Minn. – Pancreatic cancer and bile duct cancer are difficult to diagnose and often fatal because they are discovered in the advanced stages of the disease. Researchers have developed new tests that double the ability to detect bile duct and pancreatic cancers, according to a Mayo Clinic study published...
ROCHESTER, Minnesota — Mayo Clinic researchers have developed organoid models to study uveal melanoma, one of the most common types of eye cancer in adults. Their goal is to use these models to better understand how this disease works and develop treatments for unmet patient needs. Organoids are 3D models grown from patient tissue...